Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation.
Kageji, H., Momose, T., Nagamoto, Y., Togashi, N., Yasumatsu, I., Nishikawa, Y., Kihara, K., Hiramoto, K., Minami, M., Kasanuki, N., Isoyama, T., Naito, H.(2023) Bioorg Med Chem Lett 98: 129575-129575
- PubMed: 38065292 
- DOI: https://doi.org/10.1016/j.bmcl.2023.129575
- Primary Citation of Related Structures:  
8WD4 - PubMed Abstract: 
The C797S mutation is one of the major factors behind resistance to the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Herein, we describe the discovery of the 2,4-diaminonicotinamide derivative 5j, which shows potent inhibitory activity against EGFR del19/T790M/C797S and L858R/T790M/C797S. We also report the structure-activity relationship of the 2,4-diaminonicotinamide derivatives and the co-crystal structure of 5j and EGFR del19/T790M/C797S.
Organizational Affiliation: 
R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: kageji.hideaki.xa@daiichisankyo.co.jp.